Ask about this productRelated genes to: NRG1 antibody
- Gene:
- NRG1 NIH gene
- Name:
- neuregulin 1
- Previous symbol:
- HGL, NRG1-IT2
- Synonyms:
- HRG, NDF, GGF
- Chromosome:
- 8p12
- Locus Type:
- gene with protein product
- Date approved:
- 1999-03-19
- Date modifiied:
- 2015-01-28
Related products to: NRG1 antibody
Related articles to: NRG1 antibody
- Although immune checkpoint inhibitors (ICIs) have contributed to significant advances in the treatment of lung cancer, there is a lack of research investigating their efficacy in patients with non-small-cell lung cancer harboring NRG1 fusion genes. - Source: PubMed
Publication date: 2026/07/03
Yan XiyunFu XiyanLong ZhanghuiLiu LiZang YuanshengSu Chunxia - A rapidly advancing class of engineered immunoglobulins, known as bispecific antibodies (bsAbs), that bind two distinct antigens offers new approaches for tumor targeting and immune modulation. BsAbs function as immune cell engagers, immune checkpoint modulators, or signaling pathway inhibitors. They differ in half-life, stability, and tissue penetration depending on whether they exist in crystallizable fragment (Fc)-based or fragment-based formats. Although bsAbs have shown strong efficacy in hematologic malignancies, their translation to solid tumors has been limited by antigen heterogeneity, off-tumor toxicity, and the immunosuppressive tumor microenvironment. Recent clinical advancements have led to eight approved bsAbs for solid tumors, including amivantamab for (epidermal growth factor receptor) exon 20 insertion-mutated non-small cell lung cancer (NSCLC), tebentafusp for uveal melanoma, cadonilimab for cervical cancer, tarlatamab for small cell lung cancer, ivonescimab for PD-L1 (programmed death-ligand 1)-positive NSCLC, zanidatamab for HER2 (human epidermal growth factor receptor 2)-amplified biliary tract cancer, zenocutuzumab for (neuregulin 1) fusion-positive tumors, and catumaxomab for malignant ascites. These agents have demonstrated durable clinical benefit with manageable safety profiles. However, class-related toxicities such as cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and on-target off-tumor effects remain important challenges. Advances in Fc silencing, affinity tuning, and tumor-restricted activation have improved therapeutic selectivity and tolerability. Ongoing innovations include bsAb-drug conjugates, proteolysis-targeting chimeras (PROTACs), and multispecific antibody platforms designed to reprogram the tumor microenvironment and enhance immune infiltration. Biomarker-driven patient selection and rational combination strategies are expected to further improve outcomes. As engineering technologies mature, bsAbs are expected to become integral to precision oncology, expanding safe and effective immunotherapy options for patients with solid tumors. This review aims to provide a comprehensive overview of the mechanisms, clinical applications, challenges, and future directions of bsAbs in solid tumors. - Source: PubMed
Publication date: 2026/07/02
Almosa RadiyaMendoza Megan MacalaladTang Tin-YunStephen Bettzy - Research increasingly implicates neuroimmune inflammation in schizophrenia, with the epidermal growth factor (EGF) family as a potential link. This review critically evaluates EGF family members as diagnostic, risk, and treatment response markers.The most consistent finding is decreased serum EGF in chronic schizophrenia, confirmed in postmortem brain and independent of antipsychotics. First-episode data are heterogeneous, reflecting differences in medication status, population, and illness stage.Genetic studies of EGF rs4444903 show no consistent disease risk association but demonstrate a replicable, sex-specific effect on age at onset in males. Stronger evidence implicates NRG1 type IV and NRG3 polymorphisms in disease biology.Serum EGF is not a reliable treatment response marker. In summary, EGF alone is not clinically useful. Its value lies in consistent reduction in chronic patients, sex-specific effects on age at onset, and robust links of NRG1 and NRG3 to schizophrenia. - Source: PubMed
Publication date: 2026/07/02
Piskareva DariaZorkina YanaAndryushenko AlisaKostyuk Georgy - Presently, to our knowledge, there are no approved targeted therapies for neuregulin 1 gene fusion-positive (+) cholangiocarcinoma. Zenocutuzumab, a HER2 × HER3 bispecific antibody, is approved for previously treated, advanced/metastatic + non-small cell lung cancer and pancreatic adenocarcinoma. Here, we report results for 22 patients with + cholangiocarcinoma in the eNRGy trial. - Source: PubMed
Publication date: 2026/07/01
Cleary James MSpringfeld ChristophArnold DirkHollebecque AntoineGbolahan OlumideNagasaka MisakoSiena SalvatoreOpdam FransSunakawa YuCassier Philippe ATrikha GauravGort Eelke HFlorou VaiaGreil RichardLa Porte Paul FGandhi Pritesh JGarner FionaWasserman ErnestoAdeyemi SholaSchram Alison M - Neuregulin-1 (NRG-1), the natural ligand for HER3 and HER4, has been established as an essential growth factor for heart function. Prior studies have demonstrated the therapeutic potential of NRG-1 in the treatment of heart failure, but HER3 receptor activation has been a concern given its cancer association. Here, we describe the novel antibody fusion protein JK07, consisting of an antagonistic HER3 antibody and the EGF-binding domain of NRG-1. We confirm the HER3 antibody and the NRG-1 domains both retain functional activity in vitro and in vivo. Importantly, we demonstrate here for the first time that preserving HER4 stimulation by NRG1 in the presence of attenuated HER3 stimulation is sufficient to realize the therapeutic effects of NRG-1 in treatment of heart failure. Comparing JK07 to a control NRG-1 antibody fusion which does not recognize HER3, we show that JK07 can achieve equivalent recovery of ejection fraction in a rodent model of chronic heart failure. Finally, JK07 exhibited therapeutic potential in heart failure in rhesus macaques. In conclusion, this work demonstrates selective HER4 activation is sufficient for NRG-1 to improve myocardial function in multiple pre-clinical heart failure models and that JK07 holds promise as a potential therapeutic intervention for heart failure. - Source: PubMed
Publication date: 2026/03/02
Murphy Samuel LTang Wai Hong WilsonZhuang XiaoleiLi John